On August 3, Intuitive Surgical rose 4.03% in regular trading, trading near $372.89/share, with turnover of approximately $130 million. The move was driven by multiple institutional upgrades signaling valuation repair potential following the stock's sharp post-earnings selloff.

UBS upgraded Intuitive Surgical from Neutral to Buy with a $500 price target, arguing that the market has over-discounted automation risks and hospital capital expenditure concerns. The company's Q2 results showed adjusted EPS of $2.80, beating estimates by 12%, while revenue of $2.89 billion rose 19% year-over-year. Da Vinci procedure volume grew 15%, demonstrating continued monetization of the installed base.

The stock had previously plunged over 11% after the company maintained rather than raised its full-year procedure growth guidance of 13.5%-15.5% despite the earnings beat. With the stock now trading at approximately 31% below its three-year historical P/E multiple, current valuation levels are attracting institutional capital. BMO Capital Markets has identified Intuitive Surgical as a top pick, attributing sector weakness to fund flows and policy noise rather than fundamentals.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)